U.K. Set to Pay £500 Million For GSK-Sanofi COVID-19 Drug
U.K. Set to Pay £500 Million For GSK-Sanofi COVID-19 Drug
GALWAY, IRELAND--July 14, 2020--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--The U.K. government is close to inking a £500 million ($624 million) deal with GlaxoSmithKline (NYSE:GSK) (GSK) (Brentford, England) and Sanofi (NASDAQ:SNY) (Paris, France) to supply the country with up to 60 million doses of their coronavirus vaccine.
Within this article: Details proposed vaccine deal, testing timeline, related vaccine news, Sanofi plant investment in France
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Sanofi Investing Big in New French Vaccine Plants
- México registra inversiones por 2 mil millones de dólares en el sector farm...
- Mexico Registers US$2 Billion in Pharmaceutical Investments
- Chemicals, Pharma-Biotech Take Spotlight in Pennsylvania's $31 Billion of A...
- Tetra Tech at Work on More than $18.8 Billion in U.S. Projects